Long term survival with adjuvant immunotherapy after neoadjuvant chemoimmunotherapy and esophagectomy in locally advanced ESCC
Year: 2026
Type: article
Study design: Observational Study
Abstract: Postoperative adjuvant immunotherapy (aIT) represents a strategy for locally advanced esophageal squamous cell carcinoma (LA-ESCC) treated with neoadjuvant chemoimmunotherapy (nCIT) followed by esophagectomy. This multicenter retrospective cohort enrolled 418 Chinese LA-ESCC patients treated with nCIT followed by esophagectomy, split into aIT and surveillance groups. We balanced baseline confounders via 1:1 propensity score matching (PSM) and analyzed overall survival (OS) and event-free survival (EFS). With a median 48.7-month follow-up, aIT was associated with higher 4-year OS among matched patients (78.21% vs. 65.20%, HR=0.571, p = 0.012), while EFS (64.45% vs. 59.46%, HR=0.735, p = 0.114) showed no intergroup difference. The observed OS association with aIT was limited to patients without major pathological response (non-MPR). In this retrospective cohort, postoperative aIT was associated with longer overall survival specifically among non-MPR LA-ESCC patients following nCIT.
Source: iScience
Language: English
Subfield: Surgery
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,240
OpenAlex ID: W7171648578
